A suggestion to improve the results of “Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma”

to related objects

Location
Deutsche Nationalbibliothek Frankfurt am Main
Extent
1 Online-Ressource.
Language
Englisch

Bibliographic citation
A suggestion to improve the results of “Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma” ; volume:24 ; number:1 ; day:24 ; month:10 ; year:2024 ; pages:1 ; date:12.2024
Clinical and experimental medicine ; 24, Heft 1 (24.10.2024), 1, 12.2024

Creator
Arash, Majid
Contributor
SpringerLink (Online service)

DOI
10.1007/s10238-024-01504-y
URN
urn:nbn:de:101:1-2502152138042.805019224604
Rights
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Last update
15.08.2025, 7:27 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Show original at data provider

Associated

  • Arash, Majid
  • SpringerLink (Online service)

Other Objects (12)

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Emerging therapies for relapsed/refractory multiple myeloma: CAR-T and beyond

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma

Enhanced platelet function through CAR-T cell therapy in relapsed/refractory multiple myeloma

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy

Humanized CD19 CAR-T cells in relapsed/refractory B-ALL patients who relapsed after or failed murine CD19 CAR-T therapy

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

Daratumumab Plus Carfilzomib: An Optimistic Approach in Relapsed/Refractory Multiple Myeloma

tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma

tRNA-derived fragments as novel potential biomarkers for relapsed/refractory multiple myeloma

Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature

Lenalidomide enhances the efficacy of anti-BCMA CAR-T treatment in relapsed/refractory multiple myeloma: a case report and revies of the literature

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

Comparison of daratumumab-based regimens as second-line therapy in relapsed/refractory multiple myeloma

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Isatuximab with pomalidomide-dexamethasone in relapsed/refractory multiple myeloma: post-marketing surveillance in Japan

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma

Phase 1 study of isatuximab monotherapy in Chinese patients with relapsed/refractory multiple myeloma

Related objects